Factors Associated with New Onset Type 2 Diabetes Mellitus in HIV-Infected Patients at HIV Clinic, Ratchaburi Hospital
Keywords:
HIV, diabetes mellitus, antiretroviral therapy, risk factorAbstract
Objective: This is to evaluate risk factors associated with new onset type 2 diabetes mellitus and incidence of new onset type 2 diabetes mellitus in HIV clinic, including diabetic control and diabetic complication in this population.
Methods: A single center, retrospective case control study was conducted in HIV clinic Ratchaburi Hospital. A total of 75 HIV-infected patients with new-onset type 2 diabetes mellitus were selected as cases and compared with 75 consecutively patients without diabetes mellitus as controls. Data were collected from hospital electronic database from January 2009 to August 2019.
Results: During the study period, there were 1,023 patients in HIV-clinic and 91 HIV-infected patients were newly diagnosed type 2 diabetes mellitus. Incidence rate was 6.6 per 1,000 person-years of follow-up time. Median age was 50 years, 53.3% were male. From multivariate model, age (adjusted OR 1.11, 95% CI 1.04–1.18, p = .002), BMI ≥ 25 kg/m2 (adjusted OR 4.10, 95% CI 1.44–11.63, p = .008), statin exposure (adjusted OR 3.42, 95% CI 1.29–9.10, p = .014), initial FBG 100–125 mg/dL (adjusted OR 5.23, 95% CI 1.81–15.06, p = .002), and initial CD4 cell count > 250/mm3 (adjusted OR 3.73, 95% CI 1.16–12.03, p = .027) were significantly associated with new-onset type 2 diabetes mellitus. In addition, emtricitabine (FTC) exposure was associated with reduced risk of new onset type 2 diabetes mellitus (adjusted OR 0.023, 95% CI 0.08–0.65, p = .006).
Conclusions: There are multiple factors associated with new onset type 2 diabetes mellitus in HIV-infected patients including age, obesity, initial impaired fasting glucose, initial CD4 > 250 /mm3, and statin exposure. Interestingly, emtricitabine exposure is a protective factor in this population.
References
Ruxrungtham K, Chokephaibulkit K, Chetchotisakd P, et al. Thailand National Guidelines on HIV/AIDS Treatment and Prevention 2021/2022. Nonthaburi: Division of AIDS and STIs, Department of Disease Control; 2022.
Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372(9635):293–9. doi: 10.1016/S0140-6736(08)61113-7.
Samad F, Harris M, Puskas CM, et al. Incidence of diabetes mellitus and factors associated with its development in HIV-positive patients over the age of 50. BMJ Open Diabetes Res Care 2017;5(1):e000457. doi: 10.1136/bmjdrc-2017-000457.
Kalra S, Kalra B, Agrawal N, et al. Understanding diabetes in patients with HIV/AIDS. Diabetol Metab Syndr 2011;3(1):2. doi: 10.1186/1758-5996-3-2.
Butt AA, McGinnis K, Rodriguez-Barradas MC, et al. HIV infection and the risk of diabetes mellitus. AIDS 2009(23):1227–34. doi: 10.1097/QAD.0b013e32832bd7af
Paengsai N, Jourdain G, Chaiwarith R, et al. Incidence and clinical outcomes of diabetes mellitus in HIV-infected adults in Thailand: a retrospective cohort study. BMC Public Health 2018;18(1):1079. doi: 10.1186/s12889-018-5967-7.
Putcharoen O, Wattanachanya L, Sophonphan J, et al. New-onset diabetes in HIV-treated adults. AIDS 2017;31(11):1535–43. doi: 10.1097/QAD.0000000000001496.
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection recommendations for a public health approach. 2nd ed. Geneva: World Health Organization; 2016.
Paengsai N, Jourdain G, Salvadori N, et al. Recommended first-line antiretroviral therapy regimens and risk of diabetes mellitus in HIV-infected adults in resource-limited settings. Open Forum Infect Dis 2019;6(10):ofz298. doi: 10.1093/ofid/ofz298.
American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36(suppl 1):S11–66. doi: 10.2337/dc13-S011.
Levin A, Stevens P, Bilous RW, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter Suppl 2013;3(1):1–150. doi:10.1038/kisup.2012.75
Ko MJ, Jo AJ, Kim YJ, et al. Time- and Dose-Dependent Association of Statin Use With Risk of Clinically Relevant New-Onset Diabetes Mellitus in Primary Prevention: A Nationwide Observational Cohort Study. J Am Heart Assoc 2019;8(8):e011320. doi: 10.1161/JAHA.118.011320.
Lee SE, Sung JM, Cho IJ, et al. Risk of new-onset diabetes among patients treated with statins according to hypertension and gender: Results from a nationwide health-screening cohort. PLoS One 2018;13(4):e0195459. doi: 10.1371/journal.pone.0195459.
Erlandson KM, Jiang Y, Debanne SM, et al. Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy. Clin Infect Dis 2015;61(10):1566–72. doi: 10.1093/cid/civ554.
Spagnuolo V, Galli L, Poli A, et al. Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. BMC Infect Dis 2017;17(1):43. doi: 10.1186/s12879-016-2099-5.
Misra R, Chandra P, Riechman SE, et al. Relationship of ethnicity and CD4 Count with glucose metabolism among HIV patients on Highly-Active Antiretroviral Therapy (HAART). BMC Endocr Disord 2013;13:13. doi: 10.1186/1472-6823-13-13.
El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 2005;6(2):114–21. doi: 10.1111/j.1468-1293.2005.00273.x.
Lake JE, Currier JS. Metabolic disease in HIV infection. Lancet Infect Dis 2013;13(11):964–75. doi: 10.1016/S1473-3099(13)70271-8.
Bergman M, Abdul-Ghani M, Neves JS, et al. Pitfalls of HbA1c in the Diagnosis of Diabetes. J Clin Endocrinol Metab 2020;105(8):2803–11. doi: 10.1210/clinem/dgaa372.
American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of medical care in diabetes-2020. Diabetes Care 2020;43(suppl 1):S14-S31. doi: 10.2337/dc20-S002.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ลิขสิทธิ์บทความเป็นของผู้เขียนบทความ แต่หากผลงานของท่านได้รับการพิจารณาตีพิมพ์ลงวารสารแพทย์เขต 4-5 จะคงไว้ซึ่งสิทธิ์ในการตีพิมพ์ครั้งแรกด้วยเหตุที่บทความจะปรากฎในวารสารที่เข้าถึงได้ จึงอนุญาตให้นำบทความในวารสารไปใช้ประโยชน์ได้ในเชิงวิชาการโดยจำเป็นต้องมีการอ้างอิงถึงชื่อวารสารอย่างถูกต้อง แต่ไม่อนุญาตให้นำไปใช้ในเชิงพาณิชย์
